References
- Pollak MN. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov 2012; 2:778-90; PMID:22926251; http://dx.doi.org/10.1158/2159-8290.CD-12-0263
- Nevadunsky NS, Van Arsdale A, Strickler HD, Moadel A, Kaur G, Frimer M, Conroy E, Goldberg GL, Einstein MH. Metformin use and endometrial cancer survival. Gynecol Oncol 2014; 132:236-40; PMID:24189334; http://dx.doi.org/10.1016/j.ygyno.2013.10.026
- Ko EM, Walter P, Jackson A, Clark L, Franasiak J, Bolac C, Havrilesky LJ, Secord AA, Moore DT, Gehrig PA, et al. Metformin is associated with improved survival in endometrial cancer. Gynecol Oncol 2014; 132:438-42; PMID:24269517; http://dx.doi.org/10.1016/j.ygyno.2013.11.021
- Yin M, Zhou J, Gorak EJ, Quddus F. Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis. Oncologist 2013; 18:1248-55; PMID:24258613; http://dx.doi.org/10.1634/theoncologist.2013-0111
- Feliz LR, Tsimberidou AM. Anti-vascular endothelial growth factor therapy in the era of personalized medicine. Cancer Chemother Pharmacol 2013; 72:1-12; PMID:23463481; http://dx.doi.org/10.1007/s00280-013-2124-y
- Aghajanian C, Sill MW, Darcy KM, Greer B, McMeekin DS, Rose PG, Rotmensch J, Barnes MN, Hanjani P, Leslie KK. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 2011; 29:2259-65; PMID:21537039; http://dx.doi.org/10.1200/JCO.2010.32.6397
- Vandenput I, Vergote I, Leunen K, Berteloot P, Neven P, Amant F. Leuven dose-dense paclitaxel/carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma. Int J Gynecol Cancer 2009; 19:1147-51; PMID:19820384; http://dx.doi.org/10.1111/IGC.0b013e3181ad3dcb
- Nardo G, Favaro E, Curtarello M, Moserle L, Zulato E, Persano L, Rossi E, Esposito G, Crescenzi M, Casanovas O, et al. Glycolytic phenotype and AMP kinase modify the pathologic response of tumor xenografts to VEGF neutralization. Cancer Res 2011; 71:4214-25; PMID:21546569; http://dx.doi.org/10.1158/0008-5472.CAN-11-0242
- Porporato PE, Dhup S, Dadhich RK, Copetti T, Sonveaux P. Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front Pharmacol 2011; 2:49; PMID:21904528; http://dx.doi.org/10.3389/fphar.2011.00049
- Quintieri L, Selmy M, Indraccolo S. Metabolic effects of antiangiogenic drugs in tumors: Therapeutic implications. Biochem Pharmacol 2014; 89: 162-70; PMID:24607274; http://dx.doi.org/10.1016/j.bcp.2014.02.018
- Martin MJ, Hayward R, Viros A, Marais R. Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A. Cancer Discov 2012; 2:344-55; PMID:22576211; http://dx.doi.org/10.1158/2159-8290.CD-11-0280
- Shackelford DB, Abt E, Gerken L, Vasquez DS, Seki A, Leblanc M, Wei L, Fishbein MC, Czernin J, Mischel PS, et al. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell 2013; 23:143-58; PMID:23352126; http://dx.doi.org/10.1016/j.ccr.2012.12.008
- Faubert B, Vincent EE, Griss T, Samborska B, Izreig S, Svensson RU, Mamer OA, Avizonis D, Shackelford DB, Shaw RJ, et al. Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1alpha. Proc Natl Acad Sci U S A 2014; 111:2554-9; PMID:24550282; http://dx.doi.org/10.1073/pnas.1312570111